Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASTX727 plus venetoclax in adult acute myeloid leukemia
2020-004772-18Phase 2Suspended
- Sponsor
- Astex Pharmaceuticals
- Start
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of inqovi and venetoclax in acute myeloid leukemia (AML), sponsored by Astex Pharmaceuticals. Primary endpoints: Phase 1 pharmacokinetics endpoints, Phase 1 safety endpoints and 1 more. Started Feb 2022; status: suspended.
02
Drugs
inqovivenetoclax
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2020-004772-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004772-18.